Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.9% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 2(3)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07579351Phase 3Not Yet Recruiting

Corticosteroid Lumbar Epidural Analgesia for Radicular Pain 2

Role: collaborator

NCT04463251Phase 2Completed

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Role: collaborator

NCT04452474Phase 2Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

Role: collaborator

NCT03291002Phase 1Unknown

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Role: collaborator

NCT03660787Phase 2Completed

Efficacy and Dose Ranging Study of Seroguard

Role: collaborator

All 5 trials loaded